- Report
- August 2023
- 76 Pages
Global
From €3353EUR$3,495USD£2,900GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1919EUR$2,000USD£1,659GBP
- Report
- January 2022
- 200 Pages
Global
From €7196EUR$7,500USD£6,223GBP
- Report
- January 2022
- 60 Pages
Global
From €3790EUR$3,950USD£3,277GBP
- Drug Pipelines
- February 2018
- 207 Pages
Global
From €21109EUR$22,000USD£18,253GBP
- Report
- August 2022
Global
From €950EUR$990USD£821GBP
- Report
- August 2022
United States
From €1861EUR$1,940USD£1,610GBP
- Report
- August 2021
Global
From €3828EUR$3,990USD£3,310GBP
- Report
- August 2021
Europe
From €3281EUR$3,420USD£2,838GBP
- Report
- February 2021
Global
From €2840EUR$2,960USD£2,456GBP
- Clinical Trials
- March 2020
- 404 Pages
Global
From €2399EUR$2,500USD£2,074GBP
- Drug Pipelines
- August 2020
- 269 Pages
Global
From €1919EUR$2,000USD£1,659GBP
- Report
- July 2021
- 115 Pages
Global
From €3200EUR$3,573USD£2,864GBP
- Report
- April 2022
- 207 Pages
Global
From €1919EUR$2,000USD£1,659GBP
- Report
- August 2023
- 266 Pages
Global
From €3425EUR$3,570USD£2,962GBP
Diabetic Nephropathy is a type of kidney disease caused by diabetes. It is a major complication of diabetes and is the leading cause of end-stage renal disease. Endocrine and Metabolic Disorders Drugs are used to treat this condition. These drugs are used to reduce the risk of kidney damage, control blood sugar levels, and reduce the risk of cardiovascular disease. Commonly used drugs include ACE inhibitors, angiotensin receptor blockers, diuretics, and statins. Other drugs used to treat diabetic nephropathy include calcium channel blockers, alpha-glucosidase inhibitors, and insulin sensitizers.
The Diabetic Nephropathy Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Novartis, Merck, Pfizer, Sanofi, AstraZeneca, and Bristol-Myers Squibb. Other companies in the market include Eli Lilly, GlaxoSmithKline, Boehringer Ingelheim, and Takeda Pharmaceuticals. Show Less Read more